BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Langeland H, Damås JK, Mollnes TE, Ludviksen JK, Ueland T, Michelsen AE, Løberg M, Bergum D, Nordseth T, Skjærvold NK, Klepstad P. The inflammatory response is related to circulatory failure after out-of-hospital cardiac arrest: A prospective cohort study. Resuscitation 2021;170:115-25. [PMID: 34838662 DOI: 10.1016/j.resuscitation.2021.11.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Berkowitz S, Chapman J, Dori A, Gofrit SG, Maggio N, Shavit-Stein E. Complement and Coagulation System Crosstalk in Synaptic and Neural Conduction in the Central and Peripheral Nervous Systems. Biomedicines 2021;9:1950. [PMID: 34944766 DOI: 10.3390/biomedicines9121950] [Reference Citation Analysis]
3 Shinjyo N, Kagaya W, Pekna M. Interaction Between the Complement System and Infectious Agents - A Potential Mechanistic Link to Neurodegeneration and Dementia. Front Cell Neurosci 2021;15:710390. [PMID: 34408631 DOI: 10.3389/fncel.2021.710390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Das A, Behera LM, Rana S. Interaction of Human C5a with the Major Peptide Fragments of C5aR1: Direct Evidence in Support of "Two-Site" Binding Paradigm. ACS Omega 2021;6:22876-87. [PMID: 34514259 DOI: 10.1021/acsomega.1c03400] [Reference Citation Analysis]
5 Frazer-Abel A, Kirschfink M, Prohászka Z. Expanding Horizons in Complement Analysis and Quality Control. Front Immunol 2021;12:697313. [PMID: 34434189 DOI: 10.3389/fimmu.2021.697313] [Reference Citation Analysis]
6 Gomez-Arboledas A, Acharya MM, Tenner AJ. The Role of Complement in Synaptic Pruning and Neurodegeneration. Immunotargets Ther 2021;10:373-86. [PMID: 34595138 DOI: 10.2147/ITT.S305420] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Storm BS, Christiansen D, Fure H, Ludviksen JK, Lau C, Lambris JD, Woodruff TM, Brekke OL, Braaten T, Nielsen EW, Mollnes TE. Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood. J Immunol 2021;207:2828-40. [PMID: 34732467 DOI: 10.4049/jimmunol.2100308] [Reference Citation Analysis]
8 Lamers C, Mastellos DC, Ricklin D, Lambris JD. Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.01.004] [Reference Citation Analysis]
9 Witczak BJ, Pischke SE, Reisæter AV, Midtvedt K, Ludviksen JK, Heldal K, Jenssen T, Hartmann A, Åsberg A, Mollnes TE. Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival. Front Immunol 2021;12:738927. [PMID: 34759922 DOI: 10.3389/fimmu.2021.738927] [Reference Citation Analysis]
10 Fodil S, Annane D. Complement Inhibition and COVID-19: The Story so Far. Immunotargets Ther 2021;10:273-84. [PMID: 34345614 DOI: 10.2147/ITT.S284830] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Zelek WM, Morgan BP. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.02.006] [Reference Citation Analysis]
12 Holt MF, Michelsen AE, Shahini N, Bjørkelund E, Bendz CH, Massey RJ, Schjalm C, Halvorsen B, Broch K, Ueland T, Gullestad L, Nilsson PH, Aukrust P, Mollnes TE, Louwe MC. The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure. Front Immunol 2021;12:800978. [PMID: 35003128 DOI: 10.3389/fimmu.2021.800978] [Reference Citation Analysis]
13 Nielsen EW, Miller Y, Brekke O, Grond J, Duong A, Fure H, Ludviksen JK, Pettersen K, Reubsaet L, Solberg R, Johansen HT, Mollnes TE. A Novel Porcine Model of Ischemia-Reperfusion Injury After Cross-Clamping the Thoracic Aorta Revealed Substantial Cardiopulmonary, Thromboinflammatory and Biochemical Changes Without Effect of C1-Inhibitor Treatment. Front Immunol 2022;13:852119. [DOI: 10.3389/fimmu.2022.852119] [Reference Citation Analysis]
14 Wu X, Bao L, Hu Z, Yao D, Li F, Li H, Xu X, An Y, Wang X, Cao B, Zhang X. Ficolin A exacerbates severe H1N1 influenza virus infection-induced acute lung immunopathological injury via excessive complement activation. Cell Mol Immunol 2021. [PMID: 34302063 DOI: 10.1038/s41423-021-00737-1] [Reference Citation Analysis]
15 Mollnes TE, Storm BS, Brekke OL, Nilsson PH, Lambris JD. Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research – 20 years of experience and future perspectives. Seminars in Immunology 2022. [DOI: 10.1016/j.smim.2022.101604] [Reference Citation Analysis]
16 Thomas AM, Chaban V, Pischke SE, Orrem HL, Bosnes V, Sunde K, Seljeflot I, Lundqvist C, Nakstad ER, Andersen GØ, Schjalm C, Mollnes TE, Barratt-Due A. Complement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically. Mol Immunol 2021;141:273-9. [PMID: 34906905 DOI: 10.1016/j.molimm.2021.11.016] [Reference Citation Analysis]
17 Šimončičová E, Gonçalves de Andrade E, Vecchiarelli HA, Awogbindin IO, Delage CI, Tremblay MÈ. Present and future of microglial pharmacology. Trends Pharmacol Sci 2022:S0165-6147(21)00223-6. [PMID: 35031144 DOI: 10.1016/j.tips.2021.11.006] [Reference Citation Analysis]
18 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Reference Citation Analysis]
19 Li H, Chen J, Hu Y, Cai X, Tang D, Zhang P. Serum C1q Levels Have Prognostic Value for Sepsis and are Related to the Severity of Sepsis and Organ Damage. J Inflamm Res 2021;14:4589-600. [PMID: 34531674 DOI: 10.2147/JIR.S322391] [Reference Citation Analysis]
20 Deravi N, Ahsan E, Fathi M, Hosseini P, Yaghoobpoor S, Lotfi R, Pourbagheri-Sigaroodi A, Bashash D. Complement inhibition: A possible therapeutic approach in the fight against Covid-19. Rev Med Virol 2021;:e2316. [PMID: 34873779 DOI: 10.1002/rmv.2316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Plomp JJ, Huijbers MGM, Verschuuren JJGM, Borodovsky A. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies. J Neurosci Methods 2022;:109551. [PMID: 35247492 DOI: 10.1016/j.jneumeth.2022.109551] [Reference Citation Analysis]